This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kirby, M. Search for Related Content Social Bookmarking                         What's this?

Heart failure and diabetes in primary care

The Surgery, Nevells Road, Letchworth, Herts, SG6 4TS, UK, kirbym{at}globalnet.co.uk

Diabetes and cardiovascular disease, such as heart failure share many common denominators and they cannot therefore be managed 'in isolation'. The management of overall cardiovascular risk is now the cornerstone to any treatment approach. With the prevalence of both diabetes and heart failure predicted to rise, in a bid to avoid the associated increase in hospital admissions, the onus for effective diagnosis and management of both of these conditions will increasingly fall to those working in primary care. This article explores the current guidelines on managing heart failure in primary care, and specifically looks at the prevention and treatment of heart failure in those with diabetes. Current guidelines recommend angiotensin-converting enzyme (ACE) inhibitors as first-line therapy for heart failure. There is good evidence for this, as well as alternative treatments for those who cannot tolerate ACE inhibitors, or who require additional treatment.

Key Words: diabetes • heart failure • left ventricular dysfunction • ACE inhibitors.

References

• Diabetes in the UK 2004: Diabetes UK; 2004.
• British Heart Foundation. Coronary Heart Disease Statistics 2005. Chapter 2. Morbidity. In; 2005.
• De Groote P., Lamblin N., Mouquet F. et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J 2004;25:656-62.[Abstract/Free Full Text]
• Despres JP, Lamarche B., Mauriege P. et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334: 952-7.[Abstract/Free Full Text]
• Cowie MR, Fox KF, Wood DA et al. Hospitalization of patients with heart failure: a population-based study. Eur Heart J 2002;23:877-85.[Abstract/Free Full Text]
• McMurray JJV, Mc Donagh T., Morrison CE et al. Trends in hospitalization for heart failure in Scotland 1980-1990. Eur Heart J 1993;14:1158-62.[Abstract/Free Full Text]
• Quality and outcomes framework guidance: Stroke and TIA. 2006. http://www.bma.org.uk/ap.nsf/Content/qof06~clinincalind~heart
• National Service Framework for Coronary Heart Disease. London. Department of Health. 2000.
• Scottish Intercollegiate Guidelines Network. Diagnosis and treatment of heart failure due to left ventricular systolic dysfunction. Edinburgh:SIGN 35, 1999.
• NICE Guideline 5. Chronic Heart Failure. National clinical guideline for diagnosis and management in primary and secondary care 2003.
• Knowler WC, Barrett-Connor E., Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.[Abstract/Free Full Text]
• Katz DL Lifestyle and dietary modification for prevention of heart failure. Med Clin North Am 2004;88:1295-1320, xii.
• Poole-Wilson PA, Swedberg K., Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Young JB, Dunlap ME, Pfeffer MA et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004;110:2618-26.[Abstract/Free Full Text]
• The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.[Abstract]
• Vermes E., Ducharme A., Bourassa MG, Lessard M., White M., Tardif JC Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003;107:1291-6.[Abstract/Free Full Text]
• Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992;327:685-91.[Abstract]
• The AIRE study Investigators. Effect of reamipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342:821-8.[Web of Science][Medline] [Order article via Infotrieve]
• The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987;316:1429-35.[Abstract]
• Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R., Simoons ML The effect of perindopril on cardiovascular morbidity and mortality in substudy. Eur Heart J 2005;26:1369-78. patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005;26:1369-78[Abstract/Free Full Text]
• Fox KM Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Packer M., Fowler MB, Roecker EB et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-9.[Abstract/Free Full Text]
• The BHS Guidelines Working Party Guidelines for Management of Hypertension: Report of the Fourth Working Party of the British Hypertension Society, 2004 - BHS IV. J Human Hypertension 2004;18:139-85.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Dahlof B., Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Whelton PK, Barzilay J., Cushman WC et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165:1401-09.[Abstract/Free Full Text]
• Scheen AJ Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 2004;64:2537-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Gillespie EL, White CM, Kardas M., Lindberg M., Coleman CI The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005;28:2261-6.[Abstract/Free Full Text]
• Abuissa H., Jones PG, Marso SP, O'Keefe JH, Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005;46:821-6.[Abstract/Free Full Text]
• Cohn JN, Tognoni G.; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-75.[Abstract/Free Full Text]
• De P., Das G., Harley K., Nair H. Dual blockade of rennin-angiotensive system in diabetic nephropathy: Review of literature and local experience. Br J Diabetes Vasc Dis 2006;6:23-8.[Abstract/Free Full Text]
• UK Prospective Diabetes Study (UK|PDS) Group (1998). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005;28:2345-51.[Abstract/Free Full Text]
• Jones GC, Macklin JP, Alexander WD Contraindications to the use of metformin. BMJ 2003;326:4-5.[Free Full Text]
• Barnett AH Insulin-sensitizing agents - thiazolidediones (glitazones). Curr Med Opin 2002;18:31s-9s.[CrossRef]

The British Journal of Diabetes & Vascular Disease, Vol. 6, No. 5, 220-228 (2006)
DOI: 10.1177/14746514060060050401


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kirby, M. Search for Related Content Social Bookmarking                         What's this?